Stem Cell Therapy Market is worth USD 11.99 billion in 2016 and is expected to reach USD 60.94 billion by 2022, growing at a CAGR of 31.1% from 2016 to 2022.

The global stem cell therapy market report offers in-depth analysis of the market size (revenue), market share, major market segments, different geographic regions, forecast for the next five years, key market players, and premium industry trends. It also focuses on the key drivers, restraints, opportunities and challenges in the stem cell therapy market.

KEY BENEFITS OF THE REPORT:
Deeper understanding of the strategies adopted by the key players in this market to stay competitive
Granular analysis about the growth map of the market during the next five years
Comprehensive analysis of the key market players and their market share
KEY PREMIUM INDUSTRY INSIGHTS:
The increasing government initiatives and funding from various organizations, the increased spending on research and development, rapid technological advancement in genomics, and the rising awareness about the stem cell therapy are some of the factors fuelling the growth of the stem cell therapy market.
Other factors, such as the robust product pipelines and increasing approval of the new clinical trials are fuelling the growth of the stem cell therapy market further.
However, improper infrastructure, insufficient storage systems, and ethical problems are the major restraints for the stem cell therapy market.
MARKET SEGMENTATION:
This report analyzes the stem cell therapy market by the following segments:

Stem Cell Therapy Market, by Treatments
Allogeneic Stem Cell Therapy
Autologous Stem Cell Therapy
Stem Cell Therapy Market, by Applications
Oncology
Central Nervous System Diseases
Eye Diseases
Musculoskeletal Diseases
Wound & Injuries
Metabolic Disorders
Cardiovascular Disorders
Immune System Disorders
Stem Cell Therapy Market, by End-users
Hospitals
Ambulatory Surgical Centers
KEY MARKET PLAYERS:
Key players in the stem cell therapy market include:

Vericel Corporation.
Stem Cells, Inc.
Mesoblast, Ltd.
Gamida Cell
Osiris Therapeutics, Inc.
Chiesi Farmaceutici S.p.A
ReNeuron Group, plc